Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This ...

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States. Keep your retina practice on the forefront—subscribe for expert analysis and ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting. Michael ...

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics. The National Institutes of Health ...

Theodore Leng, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

The European Commission (EC) granted marketing authorization for Afqlir (aflibercept), which is a 2 mg vial kit and pre-filled syringe for intravitreal injection. This is a biosimilar to reference ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...